---
title: Magrolimab Plus Rituximab with/without Chemotherapy in Patients with Relapsed/Refractory
  Diffuse Large B-Cell Lymphoma
date: '2024-09-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39293083/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240919194257&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma
  (DLBCL) ineligible for available salvage therapies have limited options for long-term
  disease control, necessitating novel treatments. Previously, magrolimab (anti-cluster-of-differentiation-47
  antibody) plus rituximab (M+R) demonstrated ability to induce complete responses
  (CR) in R/R DLBCL. Here we report 3-year follow-up data from this phase 1b/2 study
  (NCT02953509) assessing long-term safety and efficacy of M+R, ...
disable_comments: true
---
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for available salvage therapies have limited options for long-term disease control, necessitating novel treatments. Previously, magrolimab (anti-cluster-of-differentiation-47 antibody) plus rituximab (M+R) demonstrated ability to induce complete responses (CR) in R/R DLBCL. Here we report 3-year follow-up data from this phase 1b/2 study (NCT02953509) assessing long-term safety and efficacy of M+R, ...